Shares of Ligand Pharmaceuticals plunged 12 percent Tuesday after Amgen said its multiple myeloma drug, Kyprolis, did not outperform Takeda Pharmaceutical's Velcade in a late-stage study. » Read More
Look out, market watchers, Goldman Sachs' Jan Hatzius says.
JPMorgan analysts slashed the target price of Humana from $196 to $150 after reports the DOJ may block the acquisition by Aetna.
June's jobs numbers were great, but unseasonably low May hiring has been chalked up to the weather.
Chemours — a DuPont spinoff — traded up about 16 percent, while DuPont had gained 2.5 percent.
June's massive jobs beat shows the United States is on track to achieving full employment, Jared Bernstein said.
There's an issue lurking at Gap that can't be explained away by any of the excuses it's floated past investors over the past several months.
Barracuda Network's stock leaped almost 19 percent after announcing higher-than-expected earnings.
Ed Yardeni discusses concern for slowing global growth, but still remains positive on U.S. markets.
In the global search for returns after the Brexit vote, many analysts see U.S. stocks, along with emerging markets, as the best places to put money to work.
Economists were expecting nonfarm payrolls to show growth of 175,000 for June, and the unemployment rate to rise to 4.8 percent.
Shares in Nintendo Co surged as consumers flocked to try its new Pokemon GO smartphone game.
Juno plunged more than 31 percent, a day after the FDA halted a study on a potential cancer treatment following two patients deaths.
One investment bank has just given an even more generous prediction for the future price of the precious metal.
U.S. stocks have virtually reclaimed all of their post-Brexit losses because of one thing, says Jim O'Sullivan.
Smith & Wesson rose more than 4 percent in the premarket, putting it on track to open near an all-time intraday high.
Some of the names on the move ahead of the open.
Get the best of CNBC in your inbox